Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Evento

Inhibition diminishes cell viability via PKC alpha (PKCa) in thyroid cancer cells

Campos Haedo, Mateo NicolasIcon ; Díaz Flaqué, María CelesteIcon ; Díaz Albuja, Johanna AbigailIcon ; Perona, MarinaIcon ; Debernardi, Maria MercedesIcon ; Cayrol, Maria FlorenciaIcon ; Barreiro Arcos, María LauraIcon ; Sterle, Helena AndreaIcon ; Juvenal, Guillermo JuanIcon ; Cremaschi, Graciela AliciaIcon ; Rosemblit, CinthiaIcon
Tipo del evento: Reunión
Nombre del evento: LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología
Fecha del evento: 10/11/2020
Institución Organizadora: Sociedad Argentina de Investigación Clínica; Sociedad Argentina de Fisiología; Sociedad Argentina de Inmunología;
Título de la revista: Medicina (Buenos Aires)
Editorial: Fundación Revista Medicina
Idioma: Inglés
Clasificación temática:
Bioquímica y Biología Molecular

Resumen

Thyroid carcinoma (TC) is the most common endocrine neoplasia.Its incidence has increased in the last 40 years worldwide. It comprises a group of tumors of different lineage and biological behavior.About half of TC are driven by an acquired activating mutation inthe BRAF oncogene. While targeted therapies have improved outcomes in melanoma patients, most TC patients become resistant orrecur suggesting that new or additive non-cross-reactive therapiesare needed. We have previously shown that PKCa mediates TSHand thyroid hormones proliferative effects in TC. Recent evidenceindicates that together PKCa overexpression and BRAF mutationshould contribute to tumorigenesis and resistance to anticancertherapies. We found that by inhibiting BRAF expression with RNAi inanaplastic TC cells with BRAF mutation, PKCa expression decreases as well, suggesting that the latter is found downstream of BRAF.Furthermore, a decrease in the expression of the cell proliferationmarker PCNA was observed in BRAF-depleted cells by westernblot analysis. Also, TC cells were sensitive to increasing doses ofthe BRAF inhibitor widely used in the clinic vemurafenib/PLX4032in a dose-dependent manner (p<0.0001) by Cell Titer Blue (CTB)assay. To begin to study the combined inhibition of PKC and BRAF,CTB assays were performed with increasing doses of vemurafenibin presence or absence of the PKC inhibitor GF109203X at selective concentrations in follicular TC cells carrying BRAF mutation. Weconfirmed the dose-dependency of vemurafenib and found that thecombination leads to a significant decrease in cell viability (p<0.5).Our results establish that the effective dual PKCa and BRAF blockade can significantly drive tumor proliferation inhibition. The results obtained could provide new therapeutic targets and alternatives tothe treatments currently used for this disease. Despite its increasingincidence and mortality in many cases, TC constitutes a very poorlystudied area in our country.
Palabras clave: thyroid hormones , thyroid cancer , braf , pkc
Ver el registro completo
 
Archivos asociados
Thumbnail
 
Tamaño: 237.4Kb
Formato: PDF
.
Descargar
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/182920
URL: https://www.saic.org.ar/reunion-anual
Colecciones
Eventos(BIOMED)
Eventos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Citación
Inhibition diminishes cell viability via PKC alpha (PKCa) in thyroid cancer cells; LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología ; Argentina; 2020; 1-2
Compartir

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES